Clinical Trial Update: Efficacy and Safety Study of a 4-Month Post-Renal Transplant Dose Reduction of Tacrolimus(ADEQUATE) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating efficacy and safety of reducing tacrolimus dose four months after kidney transplantation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• Tacrolimus (Tacrolimus)

Snippet

Sponsor: University Hospital, Tours | Conditions: De Novo Transplant Disease | Phase 4 | Status: UNKNOWN